| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Pranoprofen (also known as Pyranoprofen), a potent and approved non-steroidal anti-inflammatory drugs (NSAIDs), is a COX inhibitor that has been used as an anti-inflammatory drug in ophthalmology. It inhibits ER stress-induced glucose regulated protein 78 (GRP78) expression, an ER-localized molecular chaperon. Pranoprofen also inhibits ER stress-induced CCAAT/enhancer-binding protein homologous protein (CHOP) expression, an apoptotic transcription factor.
| ln Vitro |
The pretreatment of 1 h at a dose of 1 mM of pranoprofen inhibits the production of GRP78 and CHOP in glial cells caused by ER stress[1]. Dicer expression is dose-dependently increased by pranoprofen (5–25 µM; 24 h). Furthermore, H2O2 (800 µM)-induced Dicer expression in FHC cells is enhanced by 5 µM of pranoprofen[3].
|
|---|---|
| ln Vivo |
In C57BL/6 mice, oral pranoprofen (4 mg/kg/16 mg/kg; 9 days) reduces inflammation in the colon tissues, relieves colitis, and shields against colon malignancies linked to colitis[3]. Dicer is a crucial part of the RNA interference pathway and is necessary for siRNA and miRNA production.
|
| Animal Protocol |
Animal/Disease Models: DSS-induced acute colitis in C57BL/6 mice[3]
Doses: 4 mg/kg;16 mg/kg Route of Administration: Oral administration; 4 mg/ kg/16 mg/kg; 9 days Experimental Results: Alleviated inflammation in DSS-induced acute colitis. |
| References |
|
| Additional Infomation |
Pranoprofen is a pyridochromene.
|
| Molecular Formula |
C15H13NO3
|
|
|---|---|---|
| Molecular Weight |
255.27
|
|
| Exact Mass |
255.089
|
|
| CAS # |
52549-17-4
|
|
| Related CAS # |
|
|
| PubChem CID |
4888
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
465.7±33.0 °C at 760 mmHg
|
|
| Melting Point |
186 °C
|
|
| Flash Point |
235.5±25.4 °C
|
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
|
| Index of Refraction |
1.628
|
|
| LogP |
1.74
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
19
|
|
| Complexity |
346
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
TVQZAMVBTVNYLA-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C15H13NO3/c1-9(15(17)18)10-4-5-13-12(7-10)8-11-3-2-6-16-14(11)19-13/h2-7,9H,8H2,1H3,(H,17,18)
|
|
| Chemical Name |
2-(5H-chromeno[2,3-b]pyridin-7-yl)propanoic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9174 mL | 19.5871 mL | 39.1742 mL | |
| 5 mM | 0.7835 mL | 3.9174 mL | 7.8348 mL | |
| 10 mM | 0.3917 mL | 1.9587 mL | 3.9174 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03355638 | Completed | Drug: Aflibercept Injection [Eylea] Drug: Pranoprofen Eyedrops Drug: Omega-3 Supplementation |
Macular Edema | Università degli Studi di Brescia | January 2016 | Phase 4 |
| NCT03712670 | Completed | Drug: Aflibercept Drug: Pranoprofen Dietary Supplement: Carotenoids |
Retinal Disease | Università degli Studi di Brescia | January 1, 2016 | Not Applicable |
| NCT01369238 | Unknown † | Device: Bee Venom Acupuncture Therapy Drug: zaltoprofen |
Whiplash Injuries | Korean Pharmacoacupuncture Institute | June 2011 | Not Applicable |
| NCT01205958 | Unknown † | Procedure: acupuncture | Chronic Neck Pain | Kyunghee University Medical Center | December 2009 | Not Applicable |
| NCT05771194 | Completed | Drug: Routine preoperative and postoperative anti-infection therapy Drug: artificial tear therapy Procedure: Cleaning, hot compresses and massage of the meibomian gland |
Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid |
Tianjin Medical University Eye Hospital | February 1, 2021 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA